Literature DB >> 17785041

Surgery in hepatic and extrahepatic colorectal metastases.

A Favero1, E Benzoni, A Zompicchiatti, L Rossit, F Bresadola, D De Anna, A Uzzau.   

Abstract

Extrahepatic disease (EHD) has been considered a contraindication to hepatectomy. Over the last few years, some series reported interesting 5-year survival rates after resection with hepatic colorectal metastases and EHD free margins. Between August 1989 and October 2005, 116 patients underwent liver resection for colorectal metastases at Surgical Department of the University of Udine, Italy. Among these, we reviewed the data of 5 patients affected by EHD. In 3 patients there were also an anastomotic recurrence of the primary tumor, in 3 patients diaphragm was infiltrated by contiguous liver metastases. We performed in all the patients minor liver resections. We have associated the radiofrequence ablation of a lesion not surgically resectable with liver resection in one case. The surgical procedure was always considered as curative. We observed no case of operative mortality. The mean survival of the entire cohort is 23.2 months (range 4-42 months). Our study, even if based upon a limited number of patients, supports the thesis that extrahepatic disease in patients affected by colorectal cancer with hepatic metastases should not be considered as an absolute contraindication to liver resection especially for the cases in with local radical cure exeresis is achievable.

Entities:  

Mesh:

Year:  2007        PMID: 17785041

Source DB:  PubMed          Journal:  G Chir        ISSN: 0391-9005


  2 in total

1.  Video: laparoscopic right hepatectomy and partial resection of the diaphragm for liver metastases.

Authors:  Andrew A Gumbs; Abraham Leventhal; John P Hoffman
Journal:  Surg Endosc       Date:  2011-05-10       Impact factor: 4.584

Review 2.  Resection of colorectal liver metastases and extra-hepatic disease: a systematic review and proportional meta-analysis of survival outcomes.

Authors:  William J Hadden; Philip R de Reuver; Kai Brown; Anubhav Mittal; Jaswinder S Samra; Thomas J Hugh
Journal:  HPB (Oxford)       Date:  2016-02-01       Impact factor: 3.647

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.